Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging develop
- PDF / 1,502,845 Bytes
- 91 Pages / 595.276 x 790.866 pts Page_size
- 115 Downloads / 204 Views
TOPIC REVIEW
Congress of neurological surgeons systematic review and evidence‑based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma Christopher Farrell1 · Wenyin Shi2 · Alexa Bodman3 · Jeffrey J. Olson4 Received: 13 July 2020 / Accepted: 23 August 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Target population These recommendations apply to adult patients with newly diagnosed or suspected glioblastoma. Imaging Question What imaging modalities are in development that may be able to provide improvements in diagnosis, and therapeutic guidance for individuals with newly diagnosed glioblastoma? Recommendation Level III: It is suggested that techniques utilizing magnetic resonance imaging for diffusion weighted imaging, and to measure cerebral blood and magnetic spectroscopic resonance imaging of N-acetyl aspartate, choline and the choline to N-acetyl aspartate index to assist in diagnosis and treatment planning in patients with newly diagnosed or suspected glioblastoma. Surgery Question What new surgical techniques can be used to provide improved tumor definition and resectability to yield better tumor control and prognosis for individuals with newly diagnosed glioblastoma? Recommendations Level II: The use of 5-aminolevulinic acid is recommended to improve extent of tumor resection in patients with newly diagnosed glioblastoma. Level II: The use of 5-aminolevulinic acid is recommended to improve median survival and 2 year survival in newly diagnosed glioblastoma patients with clinical characteristics suggesting poor prognosis. Level III: It is suggested that, when available, patients be enrolled in properly designed clinical trials assessing the value of diffusion tensor imaging in improving the safety of patients with newly diagnosed glioblastoma undergoing surgery. Neuropathology Question What new pathology techniques and measurement of biomarkers in tumor tissue can be used to provide improved diagnostic ability, and determination of therapeutic responsiveness and prognosis for patients with newly diagnosed glioblastomas? Recommendations Level II: Assessment of tumor MGMT promoter methylation status is recommended as a significant predictor of a longer progression free survival and overall survival in patients with newly diagnosed with glioblastoma. Level II: Measurement of tumor expression of neuron-glia-2, neurofilament protein, glutamine synthetase and phosphorylated STAT3 is recommended as a predictor of overall survival in patients with newly diagnosed with glioblastoma. Level III: Assessment of tumor IDH1 mutation status is suggested as a predictor of longer progression free survival and overall survival in patients with newly diagnosed with glioblastoma.
Sponsored by the American Association of Neurological Surgeons and Congress of Neurological Surgeons Joint Section on Tumors. Reviewed for evidence-based integrity and endorsed by the American Association of Neurological Surgeons and Congress of Neur
Data Loading...
